NYSEAMERICAN:ARMP

Armata Pharmaceuticals (ARMP) Stock Price, News & Analysis

Armata Pharmaceuticals logo
$2.99 +0.33 (+12.41%)
As of 11:15 AM Eastern
This is a fair market value price provided by Massive. Learn more.

About Armata Pharmaceuticals Stock (NYSEAMERICAN:ARMP)

Advanced

Key Stats

Today's Range
$2.57
▼
$3.13
50-Day Range
$2.66
▼
$5.55
52-Week Range
$2.40
▼
$14.98
Volume
37,704 shs
Average Volume
119,239 shs
Market Capitalization
$111.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00
Consensus Rating
Moderate Buy

Company Overview

Armata Pharmaceuticals is a clinical-stage biotechnology company developing bacteriophage-based treatments for bacterial infections. Bacteriophages are viruses that infect and kill specific bacteria, and Armata’s approach is intended to target disease-causing bacteria, including strains that are difficult to treat with antibiotics.

The company’s development programs have included AP-PA02, an inhaled phage therapy being studied for Pseudomonas aeruginosa lung infections, and AP-SA02, an intravenous therapy targeting Staphylococcus aureus infections. These are investigational products, not approved medicines.

Armata was formerly known as AmpliPhi Biosciences and adopted its current name in 2019. The company is based in Los Angeles and focuses on developing its phage therapies for clinical use.

AI Generated. May Contain Errors.

Armata Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
39th Percentile Overall Score

ARMP MarketRank™: 
1.946955596915 of 5 stars

Armata Pharmaceuticals scored higher than 39% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Armata Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and no sell ratings.

  • Upside Potential

    Armata Pharmaceuticals has a consensus price target of $15.00, representing about 401.7% upside from its current price of $2.99.

  • Amount of Analyst Coverage

    Armata Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Armata Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Armata Pharmaceuticals are expected to decrease in the coming year, from $2.63 to ($1.92) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Armata Pharmaceuticals is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Armata Pharmaceuticals is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    15.84% of the float of Armata Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Armata Pharmaceuticals has a short interest ratio ("days to cover") of 9.78.
  • Change versus previous month

    Short interest in Armata Pharmaceuticals has recently increased by 1.44%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Armata Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Armata Pharmaceuticals does not have a long track record of dividend growth.

  • News Sentiment

    Armata Pharmaceuticals has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Armata Pharmaceuticals this week, compared to 1 article on an average week.
  • MarketBeat Follows

    1 people have added Armata Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Armata Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    84.50% of the stock of Armata Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    3.57% of the stock of Armata Pharmaceuticals is held by institutions.

  • Read more about Armata Pharmaceuticals' insider trading history.
Receive ARMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Armata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ARMP Stock News Headlines

Worse than socialism
Donald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.tc pixel
See More Headlines

ARMP Stock Analysis - Frequently Asked Questions

Armata Pharmaceuticals' stock was trading at $6.28 at the beginning of 2026. Since then, ARMP stock has decreased by 52.4% and is now trading at $2.99.

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) released its earnings results on Thursday, November, 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.32. The business earned $3.17 million during the quarter, compared to analysts' expectations of $450 thousand. Armata Pharmaceuticals had a negative trailing twelve-month return on equity of 35.90% and a negative net margin of 1,626.27%.

Armata Pharmaceuticals' top institutional investors include State Street Corp (0.50%), Empowered Funds LLC (0.11%), Goldman Sachs Group Inc. (0.07%) and Nisa Investment Advisors LLC (0.04%).
View institutional ownership trends
.

Shares of ARMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Armata Pharmaceuticals investors own include Advanced Micro Devices (AMD), AnaptysBio (ANAB), Arcutis Biotherapeutics (ARQT), Cypherpunk Technologies (CYPH), iBio (IBIO), Precigen (PGEN) and Applied Therapeutics (APLT).

Company Calendar

Last Earnings
11/12/2026
Today
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NYSEAMERICAN:ARMP
CIK
921114
Employees
61
Year Founded
N/A

Price Target and Rating

High Price Target
$15.00
Low Price Target
$15.00
Potential Upside/Downside
+401.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.64)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$173.80 million
Net Margins
-1,626.27%
Pretax Margin
-1,464.54%
Return on Equity
-35.90%
Return on Assets
104.60%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.12
Quick Ratio
0.12

Sales & Book Value

Annual Sales
$4.90 million
Price / Sales
22.69
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($4.68) per share
Price / Book
-0.64

Miscellaneous

Outstanding Shares
37,190,000
Free Float
5,763,000
Market Cap
$111.20 million
Optionable
Not Optionable
Beta
1.54
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

This page (NYSEAMERICAN:ARMP) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners